why choose us

First received: August 01, 2022

Clinical Trial: Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation

Study Status: Completed

Recruit Status: RECRUITING

Condition: Transthyretin Cardiac Amyloidosis

Study Type: INTERVENTIONAL


Official Title: An Open-label Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Tafamidis in Patients With Transthyretin-mediated Amyloidosis Post Orthotopic Heart Transplantation

Brief Summary: Transthyretin cardiac amyloidosis (ATTR-CA) is a relentlessly progressive disease that can progress to end stage heart failure, at which point recently approved transthyretin production silencing or structure stabilizing therapies provide no clinical benefit.For well-selected individuals, heart transplantation is an excellent therapeutic option to improve survival.Historically, concomitant liver transplantation has been used to halt the progression of non-cardiac transthyretin amyloidosis (ATTR) manifestations,…

Read more